According to filings with the U.S. Securities and Exchange Commission, Spirair is raising up to $23,576,313.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Spirair
Spirair is an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients by providing strong outcomes and a better patient experience. Were committed to developing new therapies that can easily integrate in any ENTs treatment algorithms so they can help more of their patients breathe better. Spirair got its start in the Stanford Biodesign Innovation Fellowship, a program that equips aspiring innovators with a proven, repeatable process to identify important health-related needs, invent novel health technologies to address them, and prepare to implement those products into patient care. Founders James Kintzing, Ph.D. and Brandon McCutcheon, M.D. were co-fellows in the program and identified an opportunity in the ENT space when they discovered the unmet need for a minimally invasive nasal septal deviation correction therapy to help address nasal airway obstruction. Our first product is a novel solution for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septal cartilage. The procedure can be conveniently and safely performed under local anesthesia or in any site of service as part of standard septoplasty techniques.

To learn more about Spirair, visit https://spirair.com/
Spirair Linkedin Page: https://www.linkedin.com/company/spirairinc/

Contact:
Ben Bishop, President and Chief Executive Officer
844-434-9673
https://www.linkedin.com/in/benbishop/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.